Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | brahma associated protein 60 kDa | 0.0334 | 0.8796 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0334 | 0.8796 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0334 | 0.8796 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0334 | 0.8796 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0334 | 0.8796 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0334 | 0.8796 | 0.8796 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0334 | 0.8796 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0334 | 0.8796 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.0334 | 0.8796 | 1 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0334 | 0.8796 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0334 | 0.8796 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0334 | 0.8796 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0334 | 0.8796 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0334 | 0.8796 | 0.8796 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0334 | 0.8796 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0334 | 0.8796 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0334 | 0.8796 | 0.8796 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0334 | 0.8796 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0334 | 0.8796 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0334 | 0.8796 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0334 | 0.8796 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0334 | 0.8796 | 0.8796 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0334 | 0.8796 | 1 |
Onchocerca volvulus | 0.0334 | 0.8796 | 0.5 | |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0334 | 0.8796 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.